JP2017217070A - Sanitary absorbent article - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a sanitary absorbent article which can quickly absorb discharged menstrual blood, and has high security feeling in appearance of the sanitary absorbent article after being used.SOLUTION: A sanitary absorbent article 1 comprises: an absorber 4 containing a high absorbent polymer; and a surface sheet 2 which is arranged on a skin facing surface side of the absorber 4, and which contacts a skin of a wearer when the absorbent article is worn by a wearer, as constitution members. In constitution members of the sanitary absorbent article 1, a hemagglutination agent containing member containing a hemagglutination agent, is included, for example, the absorber 4 serves as the hemagglutination agent containing member. In the hemagglutination agent containing member (for example, absorber 4), or other constitution member (second sheet 5, for example) which is arranged on a position closer to the skin of the wearer, than the hemagglutination agent containing member during wearing, and which contains no hemagglutination agent, triacyl glycerol is included.SELECTED DRAWING: Figure 2

Description

  The present invention relates to a sanitary absorbent article used for absorption of menstrual blood.

  A sanitary absorbent article such as a sanitary napkin used for menstruation has a high menstrual blood absorption capability, and it is desired that menstrual blood excreted on the topsheet is quickly absorbed by the absorbent body inside the article. However, menstrual menstrual blood may contain components such as endometrium, and is difficult to absorb because it has a higher viscosity than urine, which is the main absorption target of disposable diapers. Blood is not absorbed and remains on the top sheet, which may give the wearer a sticky feeling. Moreover, the state which can be visually confirmed about the sanitary absorbent article after absorption of menstrual blood can be an element which has a considerable influence on the reliability of the absorbent article, in particular, the sense of security against difficulty in leakage. For example, when a wearer of a sanitary absorbent article visually observes a surface sheet after wearing, the color of absorbed menstrual blood looks relatively dark and gives a strong impression to the wearer. There is a risk of relieving anxiety, and there is also a risk of visually discomfort.

  Regarding a technique related to menstrual blood absorption performance, a technique for improving the menstrual blood absorption performance of an absorbent article by applying a cationic polymer material to the absorbent article is known. For example, Patent Document 1 describes a personal care absorbent article such as a napkin or tampon that includes a porous nonwoven web material treated with a treatment agent that clumps or dissolves red blood cells in blood. . In this document, a polycation material which is a strongly positively charged polymer is used as the treatment agent. This treatment agent aggregates or dissolves red blood cells in the blood when the blood enters or passes through the absorbent article.

  Patent Document 2 describes that a blood modifying agent having a surface active action is contained in the surface sheet in order to quickly transfer menstrual blood from the surface sheet to the absorber. As examples, IOB (Inorganic Organic Balance), melting point, water solubility at 25 ° C., and weight average molecular weight are in specific ranges. According to the absorbent article described in Patent Literature 2, menstrual blood having high viscosity is unlikely to remain on the surface sheet, the surface sheet does not feel sticky, and the wearer is unlikely to feel visually uncomfortable.

Special table 2002-528232 gazette JP2013-63245A

  Although the techniques described in Patent Documents 1 and 2 have a certain effect in improving the menstrual absorption capacity of the absorbent article, the menstrual absorption capacity required for the absorbent article has been increasing in recent years, and such high demand level has been achieved. The reality is that we cannot respond sufficiently.

  The subject of this invention is related with providing the sanitary absorbent article which can absorb rapidly the excreted menstrual blood.

The present invention has a longitudinal direction corresponding to the longitudinal direction of the wearer and a lateral direction orthogonal to the longitudinal direction, and an absorbent body including a superabsorbent polymer, and is disposed on the skin-facing surface side of the absorbent body and worn when worn. A sanitary absorbent article comprising as a constituent member a surface sheet that can come into contact with a person's skin, wherein the constituent member of the absorbent article includes a hemagglutinating agent-containing member containing a hemagglutinating agent, A hematological agent containing a triacylglycerol in a hemagglutinating agent-containing member or another component that is arranged closer to the wearer's skin than the hemagglutinating agent-containing member when worn and does not contain a hemagglutinating agent An absorbent article is provided.

  According to the present invention, a sanitary absorbent article capable of quickly absorbing excreted menstrual blood is provided.

FIG. 1 is a plan view showing a skin facing surface side (surface sheet side) of a sanitary napkin that is an embodiment of the sanitary absorbent article of the present invention. FIG. 2 is a cross-sectional view schematically showing a cross section taken along line II of FIG. FIG. 3 is a perspective view schematically showing the skin facing surface side of the top sheet in the sanitary napkin shown in FIG. 1. FIG. 4 is a schematic diagram showing a menstrual blood absorption mechanism in the sanitary absorbent article of the present invention. Fig.5 (a) and FIG.5 (b) are the schematic diagrams which show the absorption mechanism of the menstrual blood in the conventional sanitary absorbent article.

  Hereinafter, the sanitary absorbent article of the present invention will be described based on preferred embodiments with reference to the drawings. 1 and 2 show a sanitary napkin 1 which is an embodiment of the sanitary absorbent article of the present invention. As shown in FIG. 1, the napkin 1 has a longitudinal direction X corresponding to the wearer's front-rear direction and a lateral direction Y orthogonal thereto, and can absorb menstrual blood, and the absorbent body 4. A surface sheet 2 that is arranged on the skin facing surface side and can come into contact with the wearer's skin when worn is provided as a constituent member.

  In this specification, the “skin-opposing surface” is a surface of the sanitary absorbent article or a component thereof (for example, the absorbent body 4) that is directed to the wearer's skin when wearing the sanitary absorbent article, that is, relative The “non-skin facing surface” is a side close to the skin of the wearer, and the “non-skin facing surface” in the sanitary absorbent article or a component thereof is opposite to the skin side when the sanitary absorbent article is worn, that is, worn relatively It is a surface that faces away from the person's skin. In addition, "at the time of wearing" here means a state in which a normal proper wearing position, that is, a correct wearing position of the sanitary absorbent article is maintained, and the sanitary absorbent article is deviated from the wearing position. Not included if in state.

  As shown in FIGS. 1 and 2, the napkin 1 includes a top sheet 2 that forms a skin facing surface, a back sheet 3 that forms a non-skin facing surface, and an absorbent body 4 interposed between both sheets 2 and 3. An absorbent main body 10 is provided. The absorbent main body 10 is disposed on the abdomen side, that is, the front side of the wearer from the excretion part facing part B, which is an area disposed opposite to the wearer's liquid excretion part (such as the vaginal opening) when worn. The front part A and the rear part C arranged on the back side of the wearer, that is, the rear side of the excretory part facing part B are provided in the vertical direction X. That is, the napkin 1 or the absorbent main body 10 is divided into three regions in the longitudinal direction X from the wearer's abdomen in the order of the front part A, the excretory part facing part B, and the rear part C. The longitudinal direction X coincides with the longitudinal direction of the napkin 1 and the absorbent main body 10, and the lateral direction Y coincides with the width direction orthogonal to the longitudinal direction of the napkin 1 and the absorbent main body 10.

The top sheet 2 covers the entire skin facing surface of the absorbent body 4, and both side edges along the longitudinal direction X are substantially at the same position as both side edges along the longitudinal direction X of the absorbent body 4. On the other hand, the back sheet 3 covers the whole area of the non-skin facing surface of the absorbent body 4 and further extends outward in the lateral direction Y from both side edges along the longitudinal direction X of the absorbent body 4 to be described later. In addition, a side flap portion 10S is formed. The back sheet 3 and the side sheet 6 are joined to each other by known joining means such as an adhesive, heat seal, ultrasonic seal, and the like at the extended portions from both side edges along the longitudinal direction X of the absorber 4. Moreover, the surface sheet 2 and the back surface sheet 3 are mutually joined by the well-known joining means in the extension part from the both ends of the vertical direction X of the absorber 4, as shown in FIG. The top sheet 2 and the back sheet 3 may be bonded to the absorber 4 with an adhesive.

  In FIG. 3, the main part of the skin facing surface of the topsheet 2 in the napkin 1 is shown enlarged. On the skin facing surface 2a of the top sheet 2 (skin facing surface of the napkin 1), depressions 20 extending in the direction intersecting the vertical direction X and the horizontal direction Y (that is, the diagonal direction) are formed in a diagonal lattice shape. The top sheet 2 is partitioned into a large number of regions by the recess 20, and a large number of partitioned regions 22 are formed. In the embodiment shown in FIG. 3, the recess 20 is formed over the entire surface sheet 2. It may replace with this and you may form the hollow part 20 in the excretion part opposing part B at least. Note that the X direction in FIG. 3 is the same direction as the direction (CD) orthogonal to the sheet flow direction at the time of manufacturing the top sheet, and is also the same as the longitudinal direction X (see FIG. 1) of the napkin 1. Moreover, the Y direction in FIG. 3 is the same direction as the flow direction (MD) of the sheet at the time of manufacturing the top sheet, and is also the same direction as the lateral direction Y (see FIG. 1) of the napkin 1.

  The surface sheet 2 will be further described. The surface sheet 2 is made of a fiber sheet such as a nonwoven fabric having a single layer structure or a multilayer structure, and a surface sheet made of a nonwoven fabric treated with a hydrophilizing agent can be preferably used. In the surface sheet 2 of the napkin 1, the whole area of the skin facing surface 2 a has a large number of depressions 20 formed in an oblique lattice shape and a plurality of projections 21 surrounded by the depressions 20, as shown in FIG. 3. It has an uneven shape. On the other hand, the non-skin facing surface (opposite surface with a second sheet 5 described later) 2b of the top sheet 2 does not substantially have an uneven shape and is substantially flat.

  The recess 20 is formed by pressing or bonding the constituent fibers of the surface sheet 2 made of a fiber sheet. Examples of means for crimping the fiber include embossing such as pressing with or without heat, and ultrasonic pressing. As a result, in the surface sheet 2, the density of the recessed portions 20 is higher than the density of the convex portions 21. That is, the recessed portion 20 is a high-density portion having a relatively high density in the topsheet 2, and the convex portion 21 (partition region 22) is a low-density portion having a relatively low density in the topsheet 2. Due to this, when the external force is applied to the top sheet 2, the recessed portion 20 easily acts as a flexible shaft for deformation. The depression 20 in the topsheet 2 according to this embodiment is formed by subjecting a fiber web formed by the card method to hot embossing. In the hollow part 20, the heat-fusible fiber which is the constituent fiber of the surface sheet 2 or the nonwoven fabric which comprises it is integrated by heat fusion. The heat-fusible fiber in the hollow part 20 does not maintain the form of the fiber because the heat-fusion component is melted.

  In the present embodiment, the recess 20 is formed only on the top sheet 2 and is not formed on both the second sheet 5 and the absorber 4 arranged on the non-skin facing surface side of the top sheet 2. . Therefore, the top sheet 2, the second sheet 5, and the absorber 4 are not joined via the recess 20.

It is preferable that the hollow part 20 is linear. Here, “linear” means that the shape of the recess 20 is not limited to a straight line as shown in FIG. 3 in a plan view, but includes a curved line, and each line may be a continuous line, or a rectangle, square, rhombus in a plan view. In addition, a large number of recesses (embossed portions, high-density portions) such as circles and crosses may be connected substantially without being spaced apart to form a continuous line as a whole. “Substantially without an interval” means that the interval between adjacent recesses is within 5 mm.

  As shown in FIG. 3, the recess 20 is formed in an oblique lattice shape. More specifically, the topsheet 2 is formed as the depressions 20 in parallel with each other and a plurality of first linear depressions 20a formed at a predetermined interval and in parallel with each other at a predetermined interval. In addition, a plurality of second linear depressions 20b are formed, and the first linear depressions 20a and the second linear depressions 20b intersect each other at a predetermined angle. Each of the first linear depression 20a and the second linear depression 20b extends linearly in a direction that intersects the vertical direction X and the horizontal direction Y (that is, an oblique direction). The width of the first linear depression 20a and the width of the second linear depression 20b may be the same or different. The interval between the first linear depressions 20a and the interval between the second linear depressions 20b may be the same or different.

Each partition area 22 is an area surrounded by a linear depression 20 (depression 20a, 20b), and has a rhombus shape in plan view in the present embodiment. Area of each divided area 22 is preferably, for example, 0.25 cm ² or more 2 cm ² or less. The partition region 22 may have a rhombus shape that is longer in the horizontal direction Y than in the vertical direction X in plan view. Or conversely, it may be a rhombus shape that is longer in the vertical direction X than in the horizontal direction Y. When the partition region 22 has a shape that is long in the lateral direction Y of the napkin 1, the topsheet 2 on which a large number of the recessed portions 20 are formed retains high rigidity in the lateral direction Y. This effectively prevents twisting and wrinkling in the state in which the napkin 1 is attached. When the napkin 1 is worn, wrinkles or wrinkles are mainly caused by the napkin 1 sandwiched between the thighs of the wearer being pressed from the lateral direction Y by the thighs. Holds a high rigidity in the lateral direction Y, that is, the partition region 22 has a shape that is longer in the lateral direction Y than the longitudinal direction X, the shape of the napkin 1 even when pressed from the lateral direction Y. Is easily maintained, and it is difficult for wrinkles and wrinkles to occur.

  Each partition region 22 is formed with a convex portion 21 that protrudes relatively to the hollow portion 20 surrounding the partition region 22, and each partition region 22 has a top portion 21 a on the skin facing surface 2 a side. It has a shape. The top portion 21 a of the convex portion 21 is located at the center of the partition region 22. The inside of the convex portion 21 is filled with the constituent fibers of the topsheet 2 and has a solid structure. In the present invention, a hollow portion other than a linear shape is not excluded, but from the viewpoint of forming a good convex portion 21, a linear hollow portion is preferable.

  Thus, the contact area with the wearer's skin of the napkin 1 reduces because the hollow part 20 and the convex part 21 are alternately arrange | positioned in the vertical direction X and the horizontal direction Y of the surface sheet 2, respectively. This effectively prevents stuffiness and rash. Moreover, the convex part 21 (partition area | region 22) is surrounded by the hollow part 20, and since it has the closed shape in planar view, compared with the case where the convex part 21 is not surrounded by the hollow part 20, Since the constituent fibers in the convex portion 21 are easily stretched in the thickness direction of the top sheet 2, the thickness of the convex portion 21 is increased, thereby 1) the liquid can permeate quickly and the liquid residue is small, and the top sheet 2. 2) Since the convex portions 21 are formed in a regular pattern, the visual impression is improved, and so on.

  In addition, as a surface sheet of an uneven structure, it may replace with the thing of the structure mentioned above, and the surface sheet of an uneven structure which has a hollow convex part. However, from the viewpoint of absorption of menstrual blood, the above-described surface sheet having an uneven structure having solid protrusions is preferable. In addition, as another example of the surface sheet of the concavo-convex structure, the ridges (convex portions) and the groove portions (concave portions) extending in the vertical direction or the horizontal direction are alternately arranged in a direction orthogonal to the extending direction. The thing of the form which is mentioned is mentioned.

  In addition, as the back surface sheet 3, various materials conventionally used for absorbent articles such as sanitary napkins can be used without particular limitation, and a moisture-permeable resin film or a moisture-impermeable resin film can be used. .

In the present embodiment, the absorbent main body 10 includes the second sheet 5. Specifically, as shown in FIG. 2, a liquid-permeable second sheet 5 is disposed between the top sheet 2 and the absorber 4. The second sheet 5 is a constituent member of an absorbent article that is also called a sublayer sheet or the like in this technical field, and improves the permeability of the liquid from the top sheet 2 to the absorbent body 4, and the surface of the liquid absorbed by the absorbent body 4. It plays a role of reducing liquid return to the sheet 2. In the present embodiment, the second sheet 5 covers substantially the entire skin facing surface of the absorbent body 4 (main body absorbent sheet 42). As the second sheet 5, a hydrophilic nonwoven fabric or a hydrophilic fiber aggregate can be used. Examples of the nonwoven fabric include an air-through nonwoven fabric, a point bond nonwoven fabric, a resin bond nonwoven fabric, a spunlace nonwoven fabric, and an airlaid nonwoven fabric. The basis weight of the second sheet 5 is preferably 10 g / m ² , more preferably 15 g / m ² or more, and preferably 50 g / m ² or less, more preferably 40 g / m ² or less. The thickness of the second sheet 5 is preferably 0.1 mm or more and 5 mm or less. In addition, it is preferable that the width | variety (length of the horizontal direction Y) of the second sheet 5 is shorter than the width | variety (length of the horizontal direction Y) of the absorber 4, and the length of the vertical direction X is absorber 4. It is preferable that the length of the napkin 1 is longer than the length in the vertical direction X. In the present embodiment, the second sheet 5 has a joint part that is partially joined to the top sheet 2 and / or the absorber 4 by an adhesive or the like provided in a stripe shape or a spiral shape.

  A pair of sides on both sides along the longitudinal direction X of the skin facing surface of the absorbent main body 10, that is, the skin facing surface of the topsheet 2, overlaps with both left and right side portions along the longitudinal direction X of the absorbent body 4 in plan view. Sheets 6 and 6 are arranged over substantially the entire length of the absorbent body 10 in the longitudinal direction X. The pair of side sheets 6 and 6 are joined to the top sheet 2 by a known joining means at joining lines 61 extending in the longitudinal direction X.

  In addition to the absorbent main body 10, the napkin 1 further includes a pair of wing portions 10 </ b> W and 10 </ b> W that extend outward in the lateral direction Y from both side portions along the vertical direction X of the excretory part facing portion B of the absorbent main body 10. have.

  In the sanitary absorbent article of the present invention, when the excretory part facing part B has the wing part 10W like the napkin 1 of the present embodiment, the longitudinal direction of the absorbent article (the longitudinal direction of the absorbent article) , Means a region having a wing portion 10W (a region sandwiched between a root along the longitudinal direction X of one wing portion 10W and a root along the longitudinal direction X of the other wing portion 10W). . The excretion part opposing part B in the absorbent article which does not have a wing part is produced when the absorbent article is folded into a three-fold individual packaging form. With respect to two fold lines (not shown) crossing in the Y direction in the middle, it means a region surrounded by the first fold line and the second fold line counted from the front end in the longitudinal direction X of the absorbent article. To do.

As shown in FIG. 1, the side flap portion 10 </ b> S projects greatly outward in the lateral direction Y at the excretory portion-facing portion B, whereby a pair of side flap portions 10 </ b> S is provided on both the left and right sides along the longitudinal direction X of the absorbent main body 10. Wing portions 10W, 10W are extended. The wing portion 10W has a substantially trapezoidal shape in which the lower base (side longer than the upper base) is located on the side of the absorbent main body 10 in a plan view as shown in FIG. The wing part adhesion part (not shown) which fixes wing part 10W to clothes, such as shorts, is formed. The wing part 10W is folded and used on the non-skin facing surface (outer surface) side of the crotch part of clothes such as shorts. The wing adhesive section is covered with a release sheet (not shown) made of a film, nonwoven fabric, paper, or the like before use.

  The absorber 4 will be described. The absorber 4 contains a superabsorbent polymer. The superabsorbent polymer contained in the absorber 4 is generally a particulate polymer, but may be a fibrous polymer. When the particulate superabsorbent polymer is used, the shape thereof may be any of a spherical shape, a block shape, a bowl shape, and an amorphous shape. As the superabsorbent polymer, generally, a polymer or copolymer of acrylic acid or an alkali metal acrylate can be used. Examples thereof include polyacrylic acid and salts thereof and polymethacrylic acid and salts thereof. As the polyacrylate and polymethacrylate, sodium salts can be preferably used. In addition, acrylic acid or methacrylic acid, maleic acid, itaconic acid, acrylamide, 2-acrylamido-2-methylpropanesulfonic acid, 2- (meth) acryloylethanesulfonic acid, 2-hydroxyethyl (meth) acrylate, styrenesulfonic acid, etc. It is also possible to use a copolymer obtained by copolymerizing the above-mentioned comonomer within a range that does not deteriorate the performance of the superabsorbent polymer. The content of the superabsorbent polymer in the absorber 4 is preferably 0.5% by mass or more, more preferably 5% by mass or more, and preferably 60% by mass or less, based on the total mass of the absorber 4. Preferably it is 50 mass% or less.

  Moreover, the absorber 4 in the present embodiment further contains hydrophilic fibers in addition to the superabsorbent polymer. Examples of the hydrophilic fiber contained in the absorbent body 4 include those obtained by hydrophilizing hydrophobic fibers and those that are hydrophilic per se, and these are used alone or in combination of two or more. Can be used. Particularly preferred are those which are themselves hydrophilic and have water retention. Preferred examples of the latter hydrophilic fibers include natural fibers, cellulosic regenerated fibers, and semi-synthetic fibers. As the hydrophilic fiber, pulp and rayon are particularly preferable, and pulp is more preferable. In addition to wood pulp such as softwood kraft pulp and hardwood kraft pulp, pulp includes non-wood pulp such as cotton pulp and straw pulp, but is not particularly limited. Moreover, you may use the crosslinked cellulose fiber which bridge | crosslinked the molecule | numerator of the cellulose fiber and / or the molecule | numerator, and the bulky cellulose fiber obtained by carrying out the mercerization process of wood pulp.

  The absorber 4 in this embodiment is formed from the absorbent sheets 41 and 42 containing hydrophilic fibers and a superabsorbent polymer. In the present invention, the term “absorbent sheet” means a sheet-like absorbent structure containing an absorbent material such as a superabsorbent polymer or hydrophilic fiber, and a stacked fiber formed by stacking an absorbent material. Differentiated. In general, the absorbent sheet is thinner and less rigid than the absorbent material stack, so the absorbent article with the absorbent sheet is flexible and comfortable to wear, and can be folded and handled compactly. Excellent in properties. From the viewpoint of more effectively utilizing the features of such an absorbent sheet, and obtaining an absorbent article having sufficient liquid diffusibility and liquid retention, and having a good wearing feeling, under the condition of no load per absorbent sheet The thickness is preferably 0.1 mm or more, more preferably 0.3 mm or more, and preferably 2 mm or less, more preferably 1.5 mm or less. As the absorbent sheet, for example, those described in Japanese Patent No. 2963647 and Japanese Patent No. 2955223 can be used. Examples of preferable absorbent sheets include adhesive strength generated in wet superabsorbent polymers and binders such as adhesives and adhesive fibers added separately, and between constituent fibers and superabsorbent polymers. A sheet-like material is formed by bonding the gaps.

As shown in FIGS. 1 and 2, the absorbent body 4 in the present embodiment is superimposed on the central absorbent sheet 41 and the central absorbent sheet 41 that are disposed to face the excretion part of the wearer when worn, and is illustrated in FIG. 1. And a main body absorbent sheet 42 having a portion 42E extending outwardly from at least a part of the peripheral edge of the central absorbent sheet 41 in a plan view as shown in FIG. Does not contain fiber. Here, the “periphery of the central absorbent sheet” means the peripheral edge of the central absorbent sheet 41 in a state of being incorporated in the napkin 1 as a sanitary absorbent article, and the central absorbent sheet 41 is shown in FIG. Thus, when it is incorporated in the napkin 1 in a folded state, it means the peripheral edge of the central absorbent sheet 41 in the folded state. That is, since the central absorbent sheet 41 in the form shown in FIG. 2 is folded in the lateral direction Y by a folding line extending in the longitudinal direction X as will be described later, the peripheral edge of the sheet 41 is in this folding line. The sheet 41 includes both side edges extending in the longitudinal direction X formed by the bent portions of the sheet 41 and both end edges extending in the lateral direction Y of the sheet 41. Further, the main body absorbent sheet 42 extends outward from at least a part of a peripheral edge formed by left and right side edges (folded portions) extending in the longitudinal direction X of the central absorbent sheet 41 and both front and rear edges extending in the lateral direction Y. The napkin 1 according to the present embodiment extends outward from the entire peripheral edge of the central absorbent sheet 41 as shown in FIG.

  As shown in FIG. 1, the central absorbent sheet 41 has a napkin 1 or absorption in the excretory part facing part B, the excretory part facing part B, and the part near the excretory part facing part B of each of the front part A and the rear part C. It arrange | positions at the center part of the horizontal direction Y of the sex main body 10. FIG. As shown in FIG. 2, the central absorbent sheet 41 has a multilayer structure formed by folding the sheet 41 itself. The folded multilayer structure of the central absorbent sheet 41 includes two sheets extending in the longitudinal direction X through a position where the sheet 41 having a substantially rectangular shape in plan view divides the sheet 41 into approximately three equal parts in the lateral direction Y. The sheet 41 is formed in a so-called three-fold state by being folded on the same surface side (skin-opposing surface side) at a fold line.

  The main body absorbent sheet 42 also has a multilayer structure formed by folding the sheet 42 itself. In the folded multilayer structure of the main body absorbent sheet 42, the sheet 42 having a substantially rectangular shape in plan view is folded on the same surface side (non-skin facing surface side) by two folding lines extending in the vertical direction X. And both end edges along the longitudinal direction X of the sheet 41 are formed by being overlapped at the center portion in the lateral direction Y, and the overlapping portion of the both end edges is a three-layer structure of the sheet 42, The portion other than the overlapping portion has a two-layer structure of the sheet 42. The folded multilayer structure of the main body absorbent sheet 42 forms the outer shape of the absorber 4.

  The absorbent body 4 in the present embodiment has a configuration in which the folded structure of one central absorbent sheet 41 is included in the folded structure of one main body absorbent sheet 42, and this central absorbent The part where the folding structure of the adhesive sheet 41 is arranged, that is, the central part in the lateral direction Y of the excretory part facing part B is a so-called middle-high part that is thicker than the peripheral part.

  As one of the main features of the sanitary absorbent article of the present invention, the constituent member of the absorbent article includes a hemagglutinating agent-containing member containing a hemagglutinating agent, and the hemagglutinating agent-containing member or wearing. It is sometimes mentioned that triacylglycerol is contained in another constituent member that is disposed closer to the wearer's skin than the hemagglutinating agent-containing member and does not contain the hemagglutinating agent. That is, the sanitary absorbent article of the present invention includes (A) a form including a component containing both hemagglutinating agent and triacylglycerol, and (B) triacylglycerol in order from the wearer's skin. The form which comprises the structural member containing this and the structural member containing a hemagglutinating agent is contained.

In general, the absorption rate and amount of water absorbed by a superabsorbent polymer vary depending on the type of water. When comparing saline and blood, blood absorbs more slowly and absorbs more than saline. Few. The reason is as follows. Blood is roughly divided into liquid components such as plasma and non-liquid components such as red blood cells, and the components absorbed by the superabsorbent polymer are liquid components such as plasma. As shown in FIG. 5A, when menstrual blood 11 comes into contact with superabsorbent polymer 14, only liquid component 12 in menstrual blood 11 is absorbed by superabsorbent polymer 14, and red blood cells that are non-liquid component 13 are high. It is not absorbed by the absorbent polymer 14. When the absorption of the liquid component 12 into the superabsorbent polymer 14 proceeds, the non-liquid component 13 that is not absorbed by the superabsorbent polymer 14 accumulates on the surface of the superabsorbent polymer 14 as shown in FIG. A film 15 is formed. Due to the formation of the coating film 15, the liquid absorption inhibition of the superabsorbent polymer 14 occurs, and the absorption rate decreases. In addition, due to the formation of the coating 15, swelling inhibition of the superabsorbent polymer 14 also occurs, and the amount of absorption decreases.

  As a result of various studies conducted by the present inventors on the means for preventing the phenomenon as shown in FIG. 5 (b) from occurring and preventing the decrease in absorption performance, a component occupying most of the non-liquid components in menstrual blood It was found that it is effective to aggregate the erythrocytes as shown in FIG. By forming the erythrocyte aggregate 16, it becomes difficult to generate a coating film of the aggregate 16, or even if the coating film 15 as shown in FIG. Since there remains a space through which the component 12 can permeate, absorption inhibition of the liquid component 12 is difficult to occur. As a result, the superabsorbent polymer 14 can sufficiently exhibit the absorption performance. Here, the absorption performance is expressed on the basis of the absorption amount and the absorption rate. The amount of absorption can be expressed as the ratio of the volume of the superabsorbent polymer 14 before absorption to the volume of the superabsorbent polymer 14 after absorption, that is, the volume swelling magnification described later. Further, the absorption rate can be expressed as the slope of the volume swell ratio of the superabsorbent polymer 14 over time.

  In the sanitary absorbent article of the present invention, the hemagglutinating agent plays a role in generating erythrocyte aggregates during menstrual blood. According to the knowledge of the present inventor, a cationic polymer is useful as a hemagglutinating agent for the following reason. Red blood cells have a red blood cell membrane on their surface. The erythrocyte membrane has a two-layer structure. This two-layer structure is composed of a red blood cell membrane skeleton as a lower layer and a lipid membrane as an upper layer. The lipid film exposed on the surface of erythrocytes contains a protein called glycophorin. Glycophorin has a sugar chain to which a sugar having an anionic charge called sialic acid is bonded at its end. As a result, erythrocytes can be treated as colloidal particles having an anionic charge. In general, an aggregating agent is used for aggregating the colloidal particles. Considering that erythrocytes are anionic colloidal particles, it is advantageous to use a cationic substance as an aggregating agent from the viewpoint of neutralizing the electric double layer of erythrocytes. Further, if the aggregating agent has a polymer chain, the polymer chains of the aggregating agent adsorbed on the surface of the erythrocyte tend to be entangled with each other, thereby promoting the aggregation of erythrocytes. Furthermore, when the aggregating agent has a functional group, it is preferable because the aggregation of erythrocytes is promoted by the interaction between the functional groups. According to the hemagglutinating agent (cationic polymer), it becomes possible to produce an aggregate of red blood cells during menstrual blood by the above mechanism of action.

  On the other hand, the triacylglycerol used in combination with the hemagglutinating agent in the sanitary absorbent article of the present invention is, according to the knowledge of the present inventor, menstrual dispersibility, particularly in menstrual blood that is not absorbed by the superabsorbent polymer. It has a function of increasing dispersibility of non-liquid components such as red blood cells. Therefore, by using a hemagglutinating agent and triacylglycerol together in a sanitary absorbent article, menstrual blood is separated into a liquid component such as plasma and a non-liquid component such as red blood cell mainly by the action of the hemagglutinating agent. At the same time, mainly by the action of triacylglycerol, the dispersibility of menstrual blood, especially non-liquid components in menstrual blood (superabsorbent polymer non-absorbing component) is improved. As a result, the menstrual blood absorption performance is improved, and the excreted menstrual blood can be rapidly absorbed.

  In particular, when the hemagglutinating agent and triacylglycerol are contained in the form of (A), that is, both the hemagglutinating agent and triacylglycerol are contained in one component of the absorbent article (for example, the absorbent body 4). In this case, when menstrual blood comes into contact with such a hemagglutinating agent-containing member, the member separates the menstrual blood into a liquid component such as plasma and a non-liquid component such as red blood cell by the hemagglutinating agent. It is presumed that the dispersion action of the non-liquid component by acylglycerol occurs almost simultaneously.

  In addition, when the hemagglutinating agent and triacylglycerol are contained in the form of (B), that is, the constituent member containing triacylglycerol without containing the hemagglutinating agent (for example, the top sheet 2 or the second sheet 5). In the case where the hemagglutinating agent-containing member (for example, the absorber 4) is disposed on the non-skin facing surface side, first, menstrual blood comes into contact with the constituent member containing triacylglycerol, and the blood While the diffusion in the surface direction is promoted, menstrual blood shifts to a component member located on the non-skin facing surface side with respect to the hemagglutinating agent-containing member. Next, in the hemagglutinating agent-containing member, menstrual blood comes into contact with the hemagglutinating agent-containing member over a wide range, which leads to effective utilization of the hemagglutinating agent-containing member. Further, the action of the hemagglutinating agent generated in a wide range of the hemagglutinating agent-containing member promotes separation / dispersion of liquid components such as plasma and non-liquid components such as erythrocytes, resulting in improved menstrual blood absorption performance. It is thought that it leads to.

  In addition, fluidity is different between liquid components such as plasma and non-liquid components such as erythrocytes, and the former has higher fluidity. Therefore, menstrual blood is liquid and non-liquid components due to the action of hemagglutinating agent and triacylglycerol. The liquid component having high fluidity permeates the sanitary absorbent article in the thickness direction and diffuses in the surface direction in preference to the non-liquid component having low fluidity. Thereby, the menstrual blood absorption part in the sanitary absorbent article of the present invention has an area on the skin facing surface side (for example, the surface sheet 2 side) compared to the non-skin facing surface side (for example, the back sheet 3 side). The color due to menstrual blood may be lightened. Therefore, when the wearer of the sanitary absorbent article of the present invention visually observes the surface sheet side of the absorbent article after its use, the wearer has a relatively small impression regarding the size of the absorption part of menstrual blood. It is difficult to give anxiety and visual discomfort to the leak. That is, the sanitary absorbent article of the present invention has a high level of security after use. Such an effect is exhibited in any of the forms (A) and (B).

  In the sanitary absorbent article of the present invention, a typical example of the hemagglutinating agent-containing member is an absorbent body. If it is the napkin 1 shown in FIG.1 and FIG.2, the form by which the hemagglutinating agent is contained in the absorber 4 which consists of an absorbent sheet 41,42 is a typical form.

  The position of the hemagglutinating agent in the hemagglutinating agent-containing member is not particularly limited, and the hemagglutinating agent may be present uniformly throughout the hemagglutinating agent-containing member, or a part of the hemagglutinating agent-containing member. However, in consideration of the above-described effects of the hemagglutinating agent, the thickness direction of the hemagglutinating agent-containing member is on the skin facing surface side surface layer portion which is the closest part from the wearer's skin. It is preferable that it is unevenly distributed. In addition, when the hemagglutinating agent is unevenly distributed in the skin facing surface side surface layer portion of the hemagglutinating agent-containing member, the non-skin facing surface side surface layer portion on the opposite side substantially contains the hemagglutinating agent. It does not have to be. As used herein, “the skin facing surface side surface layer portion of the hemagglutinating agent-containing member” is a region within 50% of the maximum thickness of the member in the thickness direction from the skin facing surface of the hemagglutinating agent-containing member (for example, the absorbent body 4). Means.

  For example, in the napkin 1 shown in FIGS. 1 and 2, when the hemagglutinating agent-containing member is the absorbent body 4 having a laminated structure of the absorbent sheets 41 and 42, the “hemagglutinating agent is the skin facing surface side surface layer portion”. As an example of the “unevenly distributed form”, only the outermost layer on the skin facing surface side in the laminated structure, that is, one layer relatively close to the top sheet 2 in the main absorbent sheet 42 of the folded two-layer structure A form in which a hemagglutinating agent is contained and the other layer does not contain a hemagglutinating agent or the content of the hemagglutinating agent is smaller than that of the outermost layer on the skin facing surface side.

Further, the position of the hemagglutinating agent in the surface direction of the hemagglutinating agent-containing member is not particularly limited. For example, in the napkin 1 shown in FIGS. 1 and 2, the hemagglutinating agent-containing member is the absorber 4. Alternatively, the hemagglutinating agent may be present uniformly over the entire skin-facing surface of the absorber 4 or may be unevenly distributed only on a part of the skin-facing surface of the absorber 4. Moreover, when forming the absorber slit 43 described later on the skin facing surface side surface portion of the absorber 4, the hemagglutinating agent may be selectively present only at the position where the absorber slit 43 is formed. However, considering the role of the hemagglutinating agent, it is preferable that the hemagglutinating agent is present at least in the excretory part facing part B where excretory fluid such as menstrual blood is concentrated.

  By the way, in this embodiment, as shown in FIG.1 and FIG.2, the absorber slit 43 extended in the vertical direction X is formed in the skin opposing surface side surface layer part of the absorber 4. As shown in FIG. The absorber slit 43 is a cut formed in the absorber 4, and at the position where the absorber slit 43 is formed, the forming material of the absorber 4 is cut or a plurality of forming materials are separated from each other than other portions. It is separated. By forming the absorber slit 43 in the absorber 4, excretion fluid such as menstrual blood that has sequentially passed through the top sheet 2 and the second sheet 5 and reached the skin facing surface of the absorber 4 is absorbed. While being easily diffused in the longitudinal direction X along the body slit 43, it is easy to penetrate in the thickness direction of the absorber 4. And the predetermined effect of this invention can be more reliably show | played combining the effect by such an absorber slit 43, and the effect by the hemagglutinating agent and triacylglycerol mentioned above.

  In the absorbent body 4, a large number of absorbent body slits 43 are scattered around the excretory part facing part B, and the above-mentioned effects can be expected for each slit 43. These many absorber slits 43 are formed in a staggered pattern as shown in FIG. That is, in the skin facing surface side surface portion of the absorbent body 4, there are a plurality of slit lines in the longitudinal direction X in which a plurality of absorbent slits 43 are linearly arranged at predetermined intervals in the lateral direction Y. In the horizontal direction Y, the absorber slits 43 are displaced from each other in the adjacent slit rows.

  As described above, the absorbent body 4 in the present embodiment has a laminated structure including the central absorbent sheet 41 and the main body absorbent sheet 42, and the absorbent slit 43 has at least the laminated structure. One layer is penetrated in the thickness direction. With such a configuration, the entire absorber 4 can be effectively used for absorption of menstrual blood. In particular, a leak-proof groove, which is a well-known technique, is formed on the skin-facing surface of the napkin 1, that is, a high-density portion (not shown) having a line-of-view line shape in which the top sheet 2, the second sheet 5, and the absorber 4 are integrally recessed. When formed, since the excretion fluid such as menstrual blood is difficult to transfer to the outside of the leak-proof groove, the portion of the absorber 4 located outside the leak-proof groove tends not to be used for liquid absorption. However, since the absorber slit 43 penetrates at least one layer of the laminated structure in the thickness direction, such inconvenience can be solved. In addition, as a planar view shape of a leak-proof groove | channel, in the excretion part opposing part B, it has the curve shape which becomes convex toward the outward of the horizontal direction Y, or the curve shape which becomes convex toward the inner side of the horizontal direction Y Those having the following are preferred.

  Moreover, when the absorber slit 43 is formed in the laminated structure of the absorbent sheets 41 and 42, the absorber slit 43 is used from the viewpoint of more surely exerting the above-described effects by the absorber slit 43. It is preferable that at least the outermost layer on the skin facing surface side in the laminated structure penetrates in the thickness direction. In the absorbent body 4 of the napkin 1 shown in FIG. 1 and FIG. 2, one layer relatively closer to the surface sheet 2 in the main body absorbent sheet 42 of the folded two-layer structure described above is the “laminate of absorbent sheets”. Since it corresponds to “the outermost layer on the skin facing surface side in the structure”, the absorber slit 43 preferably penetrates at least one layer of the main body absorbent sheet 42 in the thickness direction.

  In the absorbent body 4 having a laminated structure of the absorbent sheets 41 and 42, the absorbent slit 43 does not penetrate the entire absorbent body 4 in the thickness direction as shown in FIG. The absorber 4 is formed over substantially the entire length in the thickness direction over the opposing surface. The absorber slit 43 may penetrate the entire absorber 4 in the thickness direction. Further, when a plurality of absorber slits 43 are formed as illustrated, the depths of the plurality of absorber slits 43 may be the same or different.

Moreover, when the absorber 4 is comprised from the laminated structure of the absorbent sheet like this embodiment, compared with the case where the absorber 4 is comprised from the piled-up body formed by laminating | stacking an absorbent material. In addition, since the excretory fluid such as menstrual blood can diffuse between the layers in the laminated structure, the absorber 4 can be effectively used more effectively.

  Moreover, in this embodiment, as shown in FIG. 2, as for the absorber slit 43, the width | variety of the site | part close | similar to a wearer's skin is comparatively wide compared with the site | part far from a wearer's skin. Wide (that is, the length in the lateral direction Y is long). The width of the absorber slit 43 in the form shown in FIG. 2 gradually decreases from the skin facing surface side of the absorber 4 toward the non-skin facing surface side, and the opening end portion on the skin facing surface side of the absorber 4 is reduced. It is the widest. By forming the absorber slit 43 in this manner, menstrual blood that has passed through the top sheet 2 and the second sheet 5 in order and reached the skin facing surface of the absorber 4 can be promptly opposed to the non-skin facing of the absorber 4. It is possible to permeate to the surface side, thereby allowing menstrual blood to diffuse in the surface direction on the non-skin facing surface side while suppressing the spread of menstrual blood on the skin facing surface side. The appearance can be further improved.

  As shown in FIG. 1 and FIG. 2, when a hemagglutinating agent is contained in the skin facing surface side surface portion of the absorbent body 4 where the absorbent slit 43 is formed, the hemagglutinating agent is at least at the position where the absorbent slit 43 is formed. Is preferably present. The “absorber slit forming position” here means a portion of the absorber 4 that defines the absorber slit 43 that is a space, and more specifically, within 20 mm from the absorber slit 43. Means an area. By the presence of the hemagglutinating agent at the position where the absorber slit 43 is formed, the above-described functions can act synergistically, and the menstrual blood absorption performance can be further effectively improved.

  The absorber slit 43 can be formed according to a conventional method using a known cutting means. For example, when forming the absorber slit 43 in the absorber 4 which is the laminated structure of the absorbent sheets 41 and 42, a cutting device provided with a cutter roll and an anvil roll that receives a cutting blade of the cutter roll as cutting means Can be used. On the peripheral surface of the cutter roll, cutting blades extending in the circumferential direction of the roll are intermittently arranged in the axial length direction of the roll, and the arrangement pattern of such cutting blades is an absorber slit in the absorber 4. This corresponds to 43 arrangement patterns.

From the viewpoint of more surely achieving the above-described effects by the absorber slit 43, it is preferable to set the dimensions and the like of the absorber slit 43 as follows.
In a plan view on the skin facing surface side of the absorber 4, the width of the absorber slit 43 (the length in the lateral direction Y) is preferably 0.1 mm or more, more preferably 0.2 mm or more, and preferably 1 mm or less. More preferably, it is 0.8 mm or less.
In a plan view on the skin facing surface side of the absorber 4, the length in the longitudinal direction X of the absorber slit 43 is preferably 10 mm or more, more preferably 15 mm or more, and preferably 35 mm or less, more preferably 25 mm or less. is there.
The spacing between the adjacent absorber slits 43, 43 in the lateral direction Y is preferably 3 mm or more, more preferably 7 mm or more, and preferably 20 mm or less, more preferably 15 mm or less.
The number of the absorber slits 43 per unit area is preferably 5 or more, more preferably 10 or more, and preferably 25 when the unit area is an area of a square shape in plan view with a side of 5 cm. This is less than or equal to 20, more preferably less than or equal to 20.

In this embodiment, as shown in FIGS. 1 and 2, a surface material slit 23 is formed in the surface sheet 2 and extends in the longitudinal direction X through the surface sheet 2 in the thickness direction. Further, the second sheet 5 is also formed with a slit extending in the longitudinal direction X through the second sheet 5 in the thickness direction. The surface material slit 23, the slit of the second sheet 5 and the absorber slit 43 are formed at the same position in plan view, and these slits are integrated with each other so as to be open at the skin facing surface of the surface sheet 2. One slit having the following is formed. Such a slit is formed by, for example, turning a cutting means such as a cutter blade as a slit forming means from the top sheet 2 side to the back sheet 3 side in a state where the top sheet 2, the second sheet 5 and the absorber 4 are laminated. Can be formed by pushing. By forming the surface material slit 23, the absorption performance of excretory fluid such as menstrual blood can be further improved. The surface material slit 23, the slit of the second sheet 5, and the absorber slit 43 may not be formed at the same position in a plan view as shown in FIG. 2, and the positions may be shifted from each other.

The location of the hemagglutinating agent in the sanitary absorbent article of the present invention is as described above. That is, in the sanitary absorbent article of the present invention, the hemagglutinating agent-containing member is typically an absorbent body, and the hemagglutinating agent is preferably present on the skin-facing surface side surface layer portion of the absorbent body. More preferably, it is unevenly distributed on the skin facing surface side surface portion of the body. The content of the hemagglutinating agent in the hemagglutinating agent-containing member (for example, the absorber 4) is preferably 0.1 g / m ² or more, more preferably 0.5 g / m ² or more, more preferably 1.5 g / m. ² or more, and preferably 25 g / m ² or less, more preferably 15 g / m ² or less, more preferably 10 g / m ² or less.

  On the other hand, as described above, the position of triacylglycerol in the sanitary absorbent article of the present invention may be the hemagglutinating agent-containing member typified by an absorber, or the hemagglutinating agent is contained when worn. Other constituent members that are disposed closer to the wearer's skin than the member and do not contain a hemagglutinating agent may be used. The other constituent members, that is, the constituent members of the absorbent article containing triacylglycerol without containing the hemagglutinating agent are the top sheet 2 and / or the second sheet 5 in the napkin 1 shown in FIGS. It is. In particular, when triacylglycerol is contained in the second sheet 5, the second sheet 5 can quickly pass the excretory liquid, and the second sheet 5 can serve as a storage layer that can temporarily store the excretory liquid. In order to be able to function, even if a large amount of excretory fluid is excreted at once, the diffusion of the excretory fluid in the second sheet 5 in the surface direction is effectively suppressed, and the excreted fluid quickly reaches the absorber 4. obtain.

The content of triacylglycerol in the other component (for example, second sheet 5) is preferably 0.5 g / m ² or more, more preferably 3 g / m ² or more, more preferably 5 g / m ² or more, and Preferably it is 20 g / m ² or less, more preferably 15 g / m ² or less, more preferably 10 g / m ² or less.

  Further, when both the hemagglutinating agent and the triacylglycerol are contained in the absorber, the location of the triacylglycerol can be arbitrarily selected regardless of the location of the hemagglutinating agent. It may be present uniformly throughout the body, or may be unevenly distributed in a part of the absorbent body. However, in consideration of the above-described effects of triacylglycerol, it is worn on the absorbent body in the same manner as the hemagglutinating agent. It is preferable that it exists in the skin facing surface side surface layer part which is the site | part closest to a person's skin, and it is further more unevenly distributed in this skin facing surface side surface layer part.

For example, in the napkin 1 shown in FIGS. 1 and 2, if both the hemagglutinating agent and the triacylglycerol are present in the surface layer portion of the absorbent body 4 on the skin-facing surface side, more specifically, the skin is first It is inferred that the separation action of the menstrual blood plasma and other liquid components by the hemagglutinating agent and the non-liquid components such as erythrocytes and the dispersion of the non-liquid components by triacylglycerol occur at the opposite surface side surface layer portion. However, the separation of menstrual blood is not sufficiently performed in the skin facing surface side surface layer portion, and liquid permeation in the thickness direction is performed in preference to liquid diffusion in the surface direction. The diffusion of menstrual blood in the surface direction is relatively small. When menstrual blood passes through the absorbent body 4 in the thickness direction and reaches the non-skin facing surface side surface layer portion, the non-skin facing surface side surface layer portion is opposite to the skin facing surface side surface layer portion in the surface direction. Liquid diffusion is performed in preference to liquid permeation in the thickness direction, so liquid components such as plasma with relatively high fluidity in menstrual blood have priority over non-liquid components such as red blood cells with relatively low fluidity, Diffused in the surface direction. As a result, the menstrual blood-absorbing portion of the absorbent body 4 has a smaller area on the skin facing surface side than the non-skin facing surface side, and the color resulting from menstrual blood can be lightened. It becomes possible to give a sense of security to the person who sees the absorption part of the skin after using the napkin 1.

According to the knowledge of the present inventor, when both the hemagglutinating agent and the triacylglycerol are contained in the skin facing surface side of the absorbent body, the triacylglycerol is more per unit area than the hemagglutinating agent. A higher content is more effective in improving menstrual blood absorption performance. The difference between the content per unit area of triacylglycerol and that of the hemagglutinating agent in the surface layer portion on the skin-facing surface side of the absorber is (content per unit area of triacylglycerol) − (unit of hemagglutinating agent) The content per area) is preferably 3 g / m ² , more preferably 8
g / m ² .

  The method for containing the hemagglutinating agent and / or triacylglycerol in the constituent member of the sanitary absorbent article is not particularly limited, and depending on the type of the constituent member in which they are contained, the location in these constituent members, etc. A known liquid material application method such as coating, spraying or dipping can be appropriately used. For example, in the case of a hemagglutinating agent, a method of preparing a hemagglutinating agent-containing liquid in which the hemagglutinating agent is dissolved or dispersed in an appropriate solvent, and applying, spraying or immersing the hemagglutinating agent-containing liquid on a desired component of the absorbent article. Is mentioned.

  Hereinafter, the hemagglutinating agent used in the present invention will be described. The hemagglutinating agent used in the present invention acts to agglutinate erythrocytes in the blood and separate the aggregate from the aggregated blood cells and plasma components.

Examples of desirable hemagglutinating agents include those having the following properties.
That is, when 1000 ppm of the measurement sample agent is added to the simulated blood, at least two or more red blood cells aggregate to form an aggregate while maintaining the fluidity of the blood.
The simulated blood has a viscosity of 8 mPa · s measured using a B-type viscometer (manufactured by Toki Sangyo Co., Ltd., model number TVB-10M, measurement conditions: rotor No. 19, 30 rpm, 25 ° C., 60 seconds). The blood cell / plasma ratio of defibrinated horse blood (manufactured by Japan Biotest Laboratories, Inc.) was prepared.

Here, “the state in which the fluidity of blood is maintained” means that 10 g of the simulated blood to which 1000 ppm of the measurement sample agent is added is a screw tube (product number “Screw tube No. 4” manufactured by Marum Co., Ltd.). 5 mm, body diameter 27 mm, total length 55 mm), and when the screw tube bottle containing the simulated blood is inverted 180 degrees, the simulated menstrual blood of a volume of 60% or more flows down within 20 seconds.
Further, whether or not “two or more red blood cells aggregate to form an aggregate” is determined as follows. That is, the simulated blood to which a measurement sample agent was added at 1000 ppm was diluted 4000 times with physiological saline, and a laser diffraction / scattering type particle size distribution measuring device (manufactured by HORIBA Co., Ltd., model number: LA-950V2, measurement condition: flow type cell). The average median diameter of the volume particle diameter measured at a temperature of 25 ° C. by a laser diffraction scattering method using a measurement, a circulation speed of 1 and no ultrasonic wave corresponds to the size of an aggregate in which two or more red blood cells are aggregated. When it is 10 μm or more, it is determined that “two or more red blood cells aggregate to form an aggregate”.

The hemagglutinating agent used in the present invention is an agent that can satisfy the above definition (can express erythrocyte aggregation) by a compound that meets the above definition or a combination thereof, or a combination of compounds. That is, the hemagglutinating agent is an agent limited to those having a hemagglutinating action as defined above. Therefore, when the hemagglutinating agent contains a third component that does not meet the above definition, it is expressed as a hemagglutinating agent composition and is distinguished from the hemagglutinating agent.

  As the hemagglutinating agent used in the present invention, a cationic polymer is suitable. Examples of the cationic polymer include cationized cellulose and cationized starch such as hydroxypropyltrimonium chloride. The hemagglutinating agent used in the present invention can also contain a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate as a cationic polymer. In the present invention, the “quaternary ammonium salt” includes a compound having a plus monovalent charge at the nitrogen atom position, or a compound that generates a plus monovalent charge at the nitrogen atom position by neutralization. Specific examples thereof include a salt of a quaternary ammonium cation, a neutralized salt of a tertiary amine, and a tertiary amine having a cation in an aqueous solution. The “quaternary ammonium moiety” described below is also used in the same meaning and is a moiety that is positively charged in water. Further, in the present invention, the “copolymer” is a polymer obtained by copolymerization of two or more kinds of polymerizable monomers, and is a binary copolymer or a ternary copolymer or more. Includes both things. In the present invention, the “polycondensate” is a polycondensate obtained by polymerizing a condensate composed of two or more monomers.

  When the hemagglutinating agent used in the present invention contains a quaternary ammonium salt homopolymer and / or a quaternary ammonium salt copolymer and / or a quaternary ammonium salt polycondensate as the cationic polymer, the hemagglutination The agent may contain any one of a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer and a quaternary ammonium salt polycondensate, or any combination of two or more. May be included. Moreover, a quaternary ammonium salt homopolymer can be used individually by 1 type or in combination of 2 or more types. Similarly, the quaternary ammonium salt copolymer can be used alone or in combination of two or more. Furthermore, similarly, a quaternary ammonium salt polycondensate can be used individually by 1 type or in combination of 2 or more types.

  Of the various cationic polymers described above, in particular, the use of a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate from the viewpoint of adsorptivity to erythrocytes. preferable. In the following description, for convenience, the quaternary ammonium salt homopolymer, the quaternary ammonium salt copolymer and the quaternary ammonium salt polycondensate are collectively referred to as “quaternary ammonium salt polymer”.

  The quaternary ammonium salt homopolymer is obtained by polymerizing one type of polymerizable monomer having a quaternary ammonium moiety. On the other hand, the quaternary ammonium salt copolymer uses at least one polymerizable monomer having a quaternary ammonium moiety and, if necessary, at least one polymerizable monomer having no quaternary ammonium moiety. It was obtained by using seeds and copolymerizing them. That is, the quaternary ammonium salt copolymer is obtained by using two or more polymerizable monomers having a quaternary ammonium moiety and copolymerizing them, or having a quaternary ammonium moiety. It is obtained by copolymerizing one or more polymerizable monomers having one or more polymerizable monomers having no quaternary ammonium moiety. The quaternary ammonium salt copolymer may be a random copolymer, an alternating copolymer, a block copolymer, or a graft copolymer. The quaternary ammonium salt polycondensate is obtained by polymerizing these condensates using a condensate composed of one or more monomers having a quaternary ammonium moiety. That is, the quaternary ammonium salt polycondensate is obtained by polymerizing two or more kinds of condensates having a quaternary ammonium moiety, or quaternary ammonium moieties. And a condensate comprising one or more monomers having quaternary ammonium moieties and one or more monomers having no quaternary ammonium moiety, and obtained by condensation polymerization.

  A quaternary ammonium salt polymer is a cationic polymer having a quaternary ammonium moiety. A quaternary ammonium moiety can be generated by quaternary ammoniumation of a tertiary amine using an alkylating agent. Alternatively, the tertiary amine can be dissolved in acid or water and generated by neutralization. Or it can produce | generate by the quaternary ammonium formation by the nucleophilic reaction containing a condensation reaction. Examples of the alkylating agent include alkyl halides and dialkyl sulfates such as dimethyl sulfate and dimethyl sulfate. Of these alkylating agents, the use of dialkyl sulfate is preferable because the problem of corrosion that may occur when an alkyl halide is used does not occur. Examples of the acid include hydrochloric acid, sulfuric acid, nitric acid, acetic acid, citric acid, phosphoric acid, fluorosulfonic acid, boric acid, chromic acid, lactic acid, oxalic acid, tartaric acid, gluconic acid, formic acid, ascorbic acid, and hyaluronic acid. . In particular, it is preferable to use a quaternary ammonium salt polymer in which a tertiary amine moiety is quaternized with an alkylating agent, because the electric double layer of erythrocytes can be reliably neutralized. Quaternary ammoniumation by a nucleophilic reaction including a condensation reaction can be caused by a ring-opening polycondensation reaction of dimethylamine and epichlorohydrin or a cyclization reaction of dicyandiamide and diethylenetriamine.

  From the viewpoint of effectively generating red blood cell aggregates, the cationic polymer preferably has a molecular weight of 2000 or more, more preferably 10,000 or more, and even more preferably 30,000 or more. When the molecular weight of the cationic polymer is not less than these values, the entanglement of the cationic polymers between the erythrocytes and the crosslinking of the cationic polymer between the erythrocytes are sufficiently caused. The upper limit of the molecular weight is preferably 10 million or less, more preferably 5 million or less, and even more preferably 3 million or less. When the molecular weight of the cationic polymer is not more than these values, the cationic polymer dissolves well into menstrual blood. The molecular weight of the cationic polymer is preferably 2000 or more and 10 million or less, more preferably 2000 or more and 5 million or less, further preferably 2000 or more and 3 million or less, and more preferably 10,000 or more and 3 million or less. It is even more preferable, and it is particularly preferably 30,000 to 3,000,000. The molecular weight referred to in the present invention is a weight average molecular weight. Further, two or more kinds of cationic polymers having different molecular weights may be combined within the aforementioned molecular weight range. The molecular weight of the cationic polymer can be controlled by appropriately selecting the polymerization conditions. The molecular weight of the cationic polymer can be measured using HLC-8320GPC manufactured by Tosoh Corporation. Specific measurement conditions are as follows.

As the column, a column in which a guard column α and an analytical column α-M manufactured by Tosoh Corporation are connected in series is used at a column temperature of 40 ° C. The detector uses RI (refractive index). As a measurement sample, 1 mg of the treatment agent (quaternary ammonium salt polymer) to be measured is dissolved in 1 mL of the eluent. A copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate uses an eluent in which 150 mmol / L sodium sulfate and 1% by mass acetic acid are dissolved in water. A copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate has a molecular weight of 5900, a pullulan with a molecular weight of 47300, a pullulan with a molecular weight of 212,000, and a molecular weight of 788,000 with respect to 10 mL of the eluent. Pullulan, a pullulan mixture with 2.5 mg each dissolved, is used as the molecular weight standard. A copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate is measured at a flow rate of 1.0 mL / min and an injection amount of 100 μL. Except for a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, elution with 50 mmol / L lithium bromide and 1% by mass acetic acid dissolved in ethanol: water = 3: 7 (volume ratio) Use liquid. Except for a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, a polyethylene glycol (PEG) having a molecular weight of 106, a PEG having a molecular weight of 400, a PEG having a molecular weight of 1470, and a PEG having a molecular weight of 6450 with respect to 20 mL of the eluent. Polyethylene oxide (PEO) having a molecular weight of 50,000, PEO having a molecular weight of 235,000, PEO having a molecular weight of 875,000, and a PEG-PEO mixture in which 10 mg of each is dissolved is used as a molecular weight standard. Except for a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, the flow rate is 0.6 mL / min and the injection amount is 100 μL.

  In the case of using a quaternary ammonium salt polymer as the cationic polymer, it is preferable that the quaternary ammonium salt polymer has a flow potential of 1500 μeq / L or more from the viewpoint of more effectively generating red blood cell aggregates. , More preferably 2000 μeq / L or more, still more preferably 3000 μeq / L or more, and still more preferably 4000 μeq / L or more. When the flow potential of the quaternary ammonium salt polymer is not less than these values, the electric double layer of erythrocytes can be sufficiently neutralized. The upper limit of the streaming potential is preferably 13000 μeq / L or less, more preferably 8000 μeq / L or less, and even more preferably 6000 μeq / L or less. When the flow potential of the quaternary ammonium salt polymer is below these values, the electrical repulsion between the quaternary ammonium salt polymers adsorbed on the erythrocytes can be effectively prevented. The streaming potential of the quaternary ammonium salt polymer is preferably 1500 μeq / L or more and 13000 μeq / L, more preferably 2000 μeq / L or more and 13000 μeq / L or less, and 3000 μeq / L or more and 8000 μeq / L or less. Is more preferably 4000 μeq / L or more and 6000 μeq / L or less.

The flow potential of the quaternary ammonium salt polymer adjusts, for example, the molecular weight of the constituting cationic monomer itself, and the copolymerization molar ratio of the cationic monomer and the anionic monomer or nonionic monomer constituting the copolymer. Can be controlled. The streaming potential of the quaternary ammonium salt polymer can be measured using a streaming potential measuring device (PCD04) manufactured by Spectris Co., Ltd. Specific measurement conditions are as follows. First, hot melt bonding each member to a commercially available napkin is invalidated using a dryer or the like, and decomposed into members such as a top sheet, an absorber, and a back sheet. For each decomposed member, a multi-stage solvent extraction method from a nonpolar solvent to a polar solvent is performed to separate the treating agent used in each member to obtain a solution containing a single composition. The obtained solution was dried and solidified, and 1H-NMR (nuclear magnetic resonance method), IR (infrared spectroscopy), LC (liquid chromatography), GC (gas chromatography), MS (mass spectrometry), GPC (gel) Permeation chromatography) and fluorescent X-rays are combined to identify the structure of the treatment agent. With respect to a measurement sample in which 0.001 g of a treatment agent (quaternary ammonium salt polymer) to be measured is dissolved in 10 g of physiological saline, a 0.001N sodium polyethylene sulfonate aqueous solution (if the measurement sample has a negative charge) , 0.001N polydiallyldimethylammonium chloride aqueous solution) is titrated, and the titer XmL required until the potential difference between the electrodes disappears is measured. Thereafter, the streaming potential of the quaternary ammonium salt polymer is calculated by the following formula 1.
Streaming potential = (X + 0.190 ^* ) × 1000 Equation 1
(* Titration required for the physiological saline solution)

  In order for the cationic polymer to be successfully adsorbed on the surface of erythrocytes, it is advantageous that the cationic polymer is likely to interact with sialic acid present on the surface of erythrocytes. From this point of view, the present inventors proceeded with studies, and as a result, inorganic value / organic value (hereinafter referred to as “IOB (Inorganic Organic Balance) value”), which is the ratio between the inorganic value and the organic value of the substance. It was found that the degree of interaction between the sialic acid conjugate and the cationic polymer can be evaluated on the basis of. Specifically, it has been found advantageous to use a cationic polymer having an IOB value that is the same as or close to that of the sialic acid conjugate. The sialic acid conjugate is a compound in which sialic acid can exist in a living body, and examples thereof include a compound in which sialic acid is bound to the end of a glycolipid such as galactolipid.

In general, the properties of a substance are largely governed by various intermolecular forces between molecules, and this intermolecular force mainly consists of Van Der Waals force due to molecular mass and electrical affinity due to molecular polarity. If the Van Der Waals force, which has a great influence on changes in the properties of substances, and the electric affinity can be grasped individually, the properties of unknown substances or their mixtures can be predicted from the combination. be able to. This idea is a theory well known as “organic conceptual diagram”. Conceptual diagram of organic materials is, for example, “Organic analysis” written by Kei Fujita (Kanya Shoten, Showa 5), “Organic qualitative analysis: Systematic. Pure products” by Kyoda Fujita (Kyoritsu Shuppan, 1953), Jun Fujita Author “Reorganization Chemistry Experiments-Organic Chemistry” (Kawade Shobo, 1971),
"Systematic organic qualitative analysis (mixture)" written by Satoshi Fujita and Masami Akatsuka (Kazama Shobo, 1974), and "New version of organic conceptual diagram basics and application" by Yoshio Koda, Shiro Sato and Yoshio Honma (Sankyo Publishing, 2008)). In the organic conceptual diagram, regarding the physicochemical properties of materials, the degree of physical properties mainly due to Van Der Waals force is called “organic”, and the degree of physical properties mainly due to electrical affinity is called “inorganic”. The physical properties of substances are considered as a combination of “organic” and “inorganic”. Then, one carbon (C) is defined as organic 20, and the inorganic and organic values of various polar groups are defined as shown in Table 1 below. The sum of the values is obtained, and the ratio between the two is defined as the IOB value. In the present invention, the IOB value of the sialic acid conjugate described above is determined based on these organic and inorganic values, and the IOB value of the cationic polymer is determined based on the value.

Specifically, when the cationic polymer is a homopolymer, the inorganic value and the organic value are determined based on the repeating unit of the homopolymer, and the IOB value is calculated. For example, in the case of polydiallyldimethylammonium chloride which is a cationic polymer used in Example 1 described later (trade name “Mercoat 106” manufactured by Nippon Lubrizol Co., Ltd.), an organic value of −C− × 8 = 160, Ammo and NH4 salt × 1 = 400 inorganic value, Ring (non-aromatic single ring) × 1 = 10 inorganic value, −Cl × 1 = 40 organic value and 10 inorganic value Therefore, the sum of the inorganic values is 400 + 10 + 10 = 420, and the sum of the organic values is 160 + 40 = 200. Therefore, the IOB value is 420/200 = 2.10.

  On the other hand, when the cationic polymer is a copolymer, the IOB value is calculated by the following procedure according to the molar ratio of the monomers used for the copolymerization. That is, a copolymer is obtained from monomer A and monomer B, the organic value of monomer A is ORA, the inorganic value is INA, the organic value of monomer B is ORB, and the inorganic value is INB. Yes, when the molar ratio of monomer A / monomer B is MA / MB, the IOB value of the copolymer is calculated from the following equation.

  The IOB value of the cationic polymer thus determined is preferably 0.6 or more, more preferably 1.8 or more, further preferably 2.1 or more, 2.2 It is still more preferable that it is above. Further, the IOB value of the cationic polymer is preferably 4.6 or less, more preferably 3.6 or less, and even more preferably 3.0 or less. Specifically, the IOB value of the cationic polymer is preferably 0.6 or more and 4.6 or less, more preferably 1.8 or more and 3.6 or less, and 2.1 or more and 3.6 or less. More preferably, it is 2.2 or more and 3.0 or less. The IOB value of sialic acid is 4.25 for sialic acid alone and 3.89 for sialic acid conjugate. The sialic acid conjugate is a glycolipid in which a sugar chain in a glycolipid and sialic acid are bound, and the sialic acid conjugate has a higher organic value ratio and a lower IOB value than sialic acid alone.

  The IOB value of the cationic polymer is as described above, and the organic value itself is preferably 40 or more, more preferably 100 or more, and further preferably 130 or more. Further, it is preferably 310 or less, more preferably 250 or less, further preferably 240 or less, and further preferably 190 or less. For example, the organic value is preferably 40 or more and 310 or less, more preferably 40 or more and 250 or less, further preferably 100 or more and 240 or less, and still more preferably 130 or more and 190 or less. By setting the organic value of the cationic polymer within this range, the cationic polymer is more successfully adsorbed to erythrocytes.

  On the other hand, the inorganic value of the cationic polymer is preferably 70 or more, more preferably 90 or more, still more preferably 100 or more, still more preferably 120 or more, and 250 or more. It is particularly preferred that Further, it is preferably 790 or less, more preferably 750 or less, still more preferably 700 or less, still more preferably 680 or less, and particularly preferably 490 or less. For example, the inorganic value is preferably from 70 to 790, more preferably from 90 to 750, even more preferably from 90 to 680, even more preferably from 120 to 680, It is especially preferable that it is 250 or more and 490 or less. By setting the inorganic value of the cationic polymer within this range, the cationic polymer can be more effectively adsorbed to erythrocytes.

From the viewpoint of further successfully adsorbing the cationic polymer to erythrocytes, it is preferable that x and y satisfy the following formula A when the organic value of the cationic polymer is x and the inorganic value is y.
y = ax (A)
In the formula A, a is preferably 0.66 or more, more preferably 0.93 or more, and still more preferably 1.96 or more. Further, a is preferably 4.56 or less, more preferably 4.19 or less, and still more preferably 3.5 or less. For example, a is preferably a number from 0.66 to 4.56, more preferably from 0.93 to 4.19, and a number from 1.96 to 3.5. Is more preferable. In particular, if the organic value and the inorganic value of the cationic polymer satisfy the formula A, provided that the organic value and the inorganic value of the cationic polymer are within the above-mentioned ranges, the cationic property The polymer is likely to interact with the sialic acid conjugate, and the cationic polymer is more likely to be adsorbed to erythrocytes.

  From the viewpoint of effectively producing red blood cell aggregates, the cationic polymer is preferably water-soluble. In the present invention, “water-soluble” means that 0.05 g of a 1 mm or less powdery or 0.5 mm or less film-like cationic polymer is added to a 100 mL glass beaker (5 mmΦ) and mixed with 50 mL ion-exchanged water at 25 ° C. In this case, a stirrer chip having a length of 20 mm and a width of 7 mm is added, and the whole amount is dissolved in water within 24 hours under stirring at 600 rpm using a magnetic stirrer HPS-100 manufactured by ASONE Co., Ltd. In the present invention, as the more preferable solubility, the total amount is preferably dissolved in water within 3 hours, and the total amount is more preferably dissolved in water within 30 minutes.

  The cationic polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto. In particular, the quaternary ammonium salt polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto. The quaternary ammonium moiety is preferably present in the side chain. In this case, when the main chain and the side chain are bonded at one point, the flexibility of the side chain is difficult to be hindered, and the quaternary ammonium moiety present in the side chain is smoothly formed on the surface of the erythrocyte. Adsorbs. However, in the present invention, it is not hindered that the main chain and the side chain of the cationic polymer are bonded at two points or more. In the present invention, “bonded at one point” means that one of the carbon atoms constituting the main chain is single-bonded with one carbon atom located at the end of the side chain. . “Connected at two or more points” means that two or more of the carbon atoms constituting the main chain are each single-bonded with two or more carbon atoms located at the end of the side chain. Say.

  When the cationic polymer has a structure having a main chain and a plurality of side chains bonded thereto, for example, a quaternary ammonium salt polymer has a structure having a main chain and a plurality of side chains bonded thereto. In this case, the carbon number of each side chain is preferably 4 or more, more preferably 5 or more, and still more preferably 6 or more. The upper limit of the carbon number is preferably 10 or less, more preferably 9 or less, and still more preferably 8 or less. For example, the number of carbon atoms in the side chain is preferably 4 or more and 10 or less, more preferably 5 or more and 9 or less, and still more preferably 6 or more and 8 or less. The carbon number of the side chain is the carbon number of the quaternary ammonium moiety (cation moiety) in the side chain, and even if carbon is contained in the anion that is the counter ion, the carbon is counted. Not included. In particular, among the carbon atoms in the side chain, the number of carbon atoms from the carbon atom bonded to the main chain to the carbon atom bonded to the quaternary nitrogen is within the aforementioned range, so that the quaternary ammonium salt. This is preferable because the steric hindrance when the polymer is adsorbed on the surface of the erythrocyte is reduced.

When the quaternary ammonium salt polymer is a quaternary ammonium salt homopolymer, examples of the homopolymer include a polymer of a vinyl monomer having a quaternary ammonium moiety or a tertiary amine moiety. . In the case of polymerizing a vinyl monomer having a tertiary amine moiety, a quaternary ammonium salt homopolymer in which the tertiary amine moiety is quaternized with an alkylating agent before and / or after polymerization. Becomes a polymer, becomes a tertiary amine neutralized salt obtained by neutralizing a tertiary amine site with an acid before and / or after polymerization, or becomes a tertiary amine having a cation in an aqueous solution after polymerization. . Examples of the alkylating agent and the acid are as described above.

  In particular, the quaternary ammonium salt homopolymer preferably has a repeating unit represented by the following formula 1.

  Specific examples of the quaternary ammonium salt homopolymer include polyethyleneimine. Further, poly (2-methacryloxyethyldimethylamine quaternary salt), poly (2-methacryloxyethyltrimethylammonium salt) in which the side chain having a quaternary ammonium moiety is bonded to the main chain at one point. ), Poly (2-methacryloxyethyldimethylethylammonium methylsulfate), poly (2-acryloxyethyldimethylamine quaternary salt), poly (2-acryloxyethyltrimethylamine quaternary salt), poly (2-acryloxy) Ethyldimethylethylammonium ethyl sulfate), poly (3-dimethylaminopropylacrylamide quaternary salt), dimethylaminoethyl polymethacrylate, polyallylamine hydrochloride, cationized cellulose, polyethyleneimine, polydimethylaminopropylacrylamide, polyamidine, etc. And the like. On the other hand, examples of the homopolymer in which the side chain having a quaternary ammonium moiety is bonded to the main chain at two or more points include polydiallyldimethylammonium chloride and polydiallylamine hydrochloride.

When the quaternary ammonium salt polymer is a quaternary ammonium salt copolymer, two kinds of polymerizable monomers used for the polymerization of the quaternary ammonium salt homopolymer described above are used as the copolymer. A copolymer obtained by the above copolymerization can be used. Alternatively, as a quaternary ammonium salt copolymer, one or more polymerizable monomers used for the polymerization of the quaternary ammonium salt homopolymer described above and a polymerizable monomer having no quaternary ammonium moiety The copolymer obtained by copolymerizing using 1 or more types of bodies can be used. Furthermore, in addition to or instead of the vinyl polymerizable monomer, other polymerizable monomers such as —SO ₂ — can be used. As described above, the quaternary ammonium salt copolymer may be a binary copolymer or a ternary or higher copolymer.

  In particular, the quaternary ammonium salt copolymer has a repeating unit represented by the above-described formula 1 and a repeating unit represented by the following formula 2 to effectively produce an agglomerate of erythrocytes. It is preferable from the viewpoint.

Further, as the polymerizable monomer having no quaternary ammonium moiety, a cationic polymerizable monomer, an anionic polymerizable monomer, or a nonionic polymerizable monomer can be used. Among these polymerizable monomers, in particular, by using a cationic polymerizable monomer or a nonionic polymerizable monomer, charge cancellation with a quaternary ammonium moiety in a quaternary ammonium salt copolymer is achieved. Therefore, erythrocyte aggregation can be effectively generated. Examples of cationic polymerizable monomers include linear compounds having a cation-carrying nitrogen atom in the main chain, such as vinylpyridine as a cyclic compound having a cation-carrying nitrogen atom under a particular condition And a condensed compound of dicyandiamide and diethylenetriamine. Examples of the anionic polymerizable monomer include 2-acrylamido-2-methylpropanesulfonic acid, methacrylic acid, acrylic acid, styrenesulfonic acid, and salts of these compounds. On the other hand, examples of nonionic polymerizable monomers include vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol, propylene glycol, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, hydroxyethyl methacrylate, hydroxyethyl acrylate, methyl methacrylate, methyl Examples include acrylate, ethyl methacrylate, ethyl acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, and butyl acrylate. One of these cationic polymerizable monomers, anionic polymerizable monomers, or nonionic polymerizable monomers can be used, or any two or more of them can be used in combination. Can do. Also, two or more cationic polymerizable monomers can be used in combination, two or more anionic polymerizable monomers can be used in combination, or two or more nonionic polymerizable monomers can be used in combination. Can also be used. A quaternary ammonium salt copolymer copolymerized using a cationic polymerizable monomer, an anionic polymerizable monomer and / or a nonionic polymerizable monomer as a polymerizable monomer has a molecular weight of However, as described above, it is preferably 10 million or less, particularly preferably 5 million or less, and particularly preferably 3 million or less (the same applies to quaternary ammonium salt copolymers exemplified below).

A polymerizable monomer having a functional group capable of hydrogen bonding can also be used as the polymerizable monomer having no quaternary ammonium moiety. When such a polymerizable monomer is used for copolymerization, and when erythrocytes are aggregated using a quaternary ammonium salt copolymer obtained therefrom, a hard aggregate is likely to be formed. Absorption performance is less likely to be disturbed. Examples of the functional group capable of hydrogen bonding include —OH, —NH ₂ , —C
HO, -COOH, -HF, -SH and the like can be mentioned. Examples of polymerizable monomers having functional groups capable of hydrogen bonding include hydroxyethyl methacrylate, vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol, propylene glycol, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, Examples thereof include hydroxyethyl methacrylate and hydroxyethyl acrylate. In particular, hydroxyethyl methacrylate, 2-hydroxyethyl methacrylate, hydroxyethyl acrylate, dimethylacrylamide, and the like, in which hydrogen bonds work strongly, are preferable because the adsorption state of quaternary ammonium salt polymers on erythrocytes is stabilized. These polymerizable monomers can be used individually by 1 type or in combination of 2 or more types.

  As the polymerizable monomer having no quaternary ammonium moiety, a polymerizable monomer having a functional group capable of hydrophobic interaction can also be used. By using such a polymerizable monomer for copolymerization, the same advantageous effect as that in the case of using the polymerizable monomer having a functional group capable of hydrogen bonding described above, that is, the hardness of erythrocytes The effect that it becomes easy to produce an agglomerate is produced. Examples of functional groups capable of hydrophobic interaction include alkyl groups such as methyl, ethyl, and butyl groups, phenyl groups, alkylnaphthalene groups, and fluorinated alkyl groups. Examples of polymerizable monomers having functional groups capable of hydrophobic interaction include methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, butyl acrylate, styrene, etc. Is mentioned. In particular, methyl methacrylate, methyl acrylate, butyl methacrylate, butyl acrylate, etc., which have a strong hydrophobic interaction and do not significantly reduce the solubility of the quaternary ammonium salt polymer, are adsorbed to erythrocytes by the quaternary ammonium salt polymer. Is preferable because of stabilization. These polymerizable monomers can be used individually by 1 type or in combination of 2 or more types.

  The molar ratio of the polymerizable monomer having a quaternary ammonium moiety and the polymerizable monomer having no quaternary ammonium moiety in the quaternary ammonium salt copolymer is the quaternary ammonium salt. It is preferable that the red blood cells are appropriately adjusted so as to be sufficiently aggregated by the ammonium salt copolymer. Or it is preferable to adjust so that the streaming potential of a quaternary ammonium salt copolymer may become the value mentioned above. Or it is preferable to adjust so that IOB of a quaternary ammonium salt copolymer may become the value mentioned above. In particular, the molar ratio of the polymerizable monomer having a quaternary ammonium moiety in the quaternary ammonium salt copolymer is preferably 10 mol% or more, more preferably 22 mol% or more, and 32 mol. % Or more, more preferably 38 mol% or more. Further, it is preferably 100 mol% or less, more preferably 80 mol% or less, still more preferably 65 mol% or less, and even more preferably 56 mol% or less. Specifically, the molar ratio of the polymerizable monomer having a quaternary ammonium moiety is preferably 10 mol% or more and 100 mol% or less, more preferably 22 mol% or more and 80 mol% or less, It is more preferably 32 mol% or more and 65 mol% or less, and further preferably 38 mol% or more and 56 mol% or less.

When the quaternary ammonium salt polymer is a quaternary ammonium salt polycondensate, as the polycondensate, a condensate composed of one or more monomers having the quaternary ammonium moiety described above is used. Polycondensates obtained by polymerizing these condensates can be used. Specific examples include dicyandiamide / diethylenetriamine polycondensate, dimethylamine / epichlorohydrin polycondensate, and the like.

  The above-described quaternary ammonium salt homopolymer and quaternary ammonium salt copolymer can be obtained by a homopolymerization method or a copolymerization method of a vinyl polymerizable monomer. As the polymerization method, for example, radical polymerization, living radical polymerization, living cation polymerization, living anion polymerization, coordination polymerization, ring-opening polymerization, polycondensation and the like can be used. The polymerization conditions are not particularly limited, and the conditions under which the quaternary ammonium salt polymer having the target molecular weight, streaming potential, and / or IOB value can be obtained may be appropriately selected.

  In addition to the polycation (cationic polymer), the hemagglutinating agent used in the present invention includes one third component such as a solvent, a plasticizer, a fragrance, an antibacterial / deodorant, and a skin care agent. The composition may be applied in the form of the composition (hemocglutinating agent composition) contained above. As the solvent, water, a water-soluble organic solvent such as a saturated aliphatic monohydric alcohol having 1 to 4 carbon atoms, or a mixed solvent of the water-soluble organic solvent and water can be used. As the plasticizer, glycerin, polyethylene glycol, propylene glycol, ethylene glycol, 1,3-butanediol, or the like can be used. As a fragrance | flavor, the fragrance | flavor which has the green herbal-like fragrance described in patent 4776407, the extract of a plant, the extract of citrus fruits, etc. can be used. As an antibacterial / deodorant, it is polymerized from a cancrinite-like mineral containing a metal having antibacterial properties described in Japanese Patent No. 4526271, and a polymerizable monomer having a phenyl group described in Japanese Patent No. 4587928. Porous polymers, quaternary ammonium salts, activated carbon, clay minerals and the like described in Japanese Patent No. 4651392 can be used. As the skin care agent, plant extracts, collagen, natural moisturizing ingredients, moisturizing agents, keratin softening agents, anti-inflammatory agents and the like described in Japanese Patent No. 4084278 can be used.

  The proportion of the cationic polymer in the hemagglutinating agent composition is preferably 1% by mass or more, more preferably 3% by mass or more, and further preferably 5% by mass or more. Further, it is preferably 50% by mass or less, more preferably 30% by mass or less, and still more preferably 10% by mass or less. By setting the proportion of the cationic polymer in the hemagglutinating agent composition within this range, an effective amount of the cationic polymer can be imparted to the absorbent article.

  Hereinafter, the triacylglycerol used in the present invention will be described. As the triacylglycerol used in the present invention, those having a blood modifying action, specifically, a surface active action and a property having low affinity with menstrual blood can be used. One kind of triacylglycerol having a qualitative action can be used alone or in combination of two or more kinds. Among the triacylglycerols having a blood modifying action, a triester of a fatty acid having 8 to 20 carbon atoms and glycerin is preferably used in the present invention because of its low affinity with menstrual blood. Examples of commercially available triacylglycerol that can be used in the present invention include trade name “Panasate 810S” manufactured by NOF Corporation.

Although the present invention has been described above, the present invention is not limited to the above-described embodiments, and can be appropriately changed without departing from the spirit of the present invention. For example, in the above-described embodiment, the absorbent body is composed only of the absorbent sheet, but may be composed only of the stacked body formed by stacking the absorbent material, and includes both. May be. Moreover, the multilayer structure of the absorbent sheet in the absorbent body may be formed by folding a single absorbent sheet as in the above embodiment, or a plurality of absorbent sheets may be stacked without being folded. The configuration may be the same, or may be a configuration in which both configurations are combined. Further, when the absorbent body includes an absorbent core containing an absorbent material such as a superabsorbent polymer and hydrophilic fibers, and a liquid-permeable core wrap sheet that covers the absorbent core, The sex core may have a form containing both hemagglutinating agent and triacylglycerol, or the absorbent core may contain a hemagglutinating agent and the core wrap sheet may contain triacylglycerol.

  The present invention can be applied to all articles used for absorption of menstrual blood. Examples of such articles include, but are not limited to, panty liners and tampons in addition to sanitary napkins as in the above embodiment.

〔Example〕
Hereinafter, the present invention will be described more specifically with reference to examples, but the present invention is not limited to such examples.

[Example 1]
A sanitary napkin having the same basic configuration as that of the sanitary napkin 1 shown in FIGS. 1 and 2 was produced and used as a sample of Example 1. As the top sheet and the second sheet, those prepared by the method described later are used, and the two sheets are bonded to each other with a SEBM hot melt adhesive coated in a spiral basis weight of 3 g / m ² using a spray gun. did. A moisture-permeable resin film was used as the back sheet.
A folded multilayer structure of an absorbent sheet was used as the absorbent, and the absorbent sheet was produced according to the method described in Japanese Patent No. 2963647. Each produced absorbent sheet has a wood pulp content of 60% by mass, a superabsorbent polymer content of 40% by mass, a basis weight of 75 g / m ² ,
The thickness under no load was 0.5 mm. As the superabsorbent polymer, Aqualic CA manufactured by Nippon Shokubai Co., Ltd. was used.
A hemagglutinating agent and triacylglycerol were respectively applied to the entire surface layer portion of the absorbent body facing the skin. More specifically, referring to FIG. 2, a 5% aqueous solution of a commercially available hemagglutinating agent is applied to the entire one layer relatively closer to the surface sheet 2 in the main absorbent sheet 42 having a folded two-layer structure. Was applied and dried, and a commercially available triacylglycerol was applied as it was to the hemagglutinating agent applied part and dried. The application amount of the hemagglutinating agent was 1.5 g / m ² in terms of solid content, and the application amount of triacylglycerol was 5 g / m ² in terms of solid content. As a hemagglutinating agent, a product name “MARCOAT 106” (cationic polymer, weight average molecular weight: 15,000, IOB value 2.10, flow potential 7345 μeq / L) manufactured by Nippon Lubrizol Co., Ltd. is used. The product name “Panasate 810S” manufactured by NOF Corporation was used.
Absorber slits were formed in the pattern shown in FIG. 1 on the skin-facing surface side of the absorber coated with a hemagglutinating agent and triacylglycerol. More specifically, in a state where the top sheet, the second sheet, and the absorber are laminated, the cutter blade is pushed toward the back sheet side from the top sheet side, thereby making an integral cut in these, FIG. Slits as shown, that is, surface material slits, second sheet slits and absorber slits were formed. The absorber slit formed in this manner was over the substantially entire length in the thickness direction of the absorber from the skin facing surface of the absorber to the vicinity of the non-skin facing surface. Each of the surface material slit, the second sheet slit and the absorber slit has a lateral length, that is, a width of 0.5 mm, a longitudinal length of 20 mm, an interval between adjacent absorber slits in the lateral direction of 14 mm, and a unit area of 5 cm square. The number was 11.

(Preparation of surface sheet)
A core-sheath type composite fiber (core is polypropylene and sheath is polyethylene) having a fiber diameter of 4.0 dtex elongation ratio of 6% and a non-extendable core-sheath type composite fiber (core is polyethylene terephthalate, sheath is 3.3 dtex) Polyethylene) is passed through a card machine at a ratio of 50% by mass to form a web, the web is introduced into a heat embossing device, and a linear depression 20 (first linear depression) is formed on the web. 20a and a plurality of second linear depressions 20b) were formed. Next, the web was introduced into a hot air spraying apparatus, and hot air treatment was performed by air-through processing to obtain a surface sheet having a partitioned region 22 partitioned by a linear recess 20. The formation pattern of the linear depressions 20 of the obtained surface sheet is the pattern shown in FIG. 3, and the width of each of the first and second linear depressions 20a and 20b is 0.5 mm, the first linear The interval between the recesses 20a and the interval between the second linear recesses 20b is 6 mm, and the angle formed between the first linear recess 20a and the second linear recess 20b is 56 °. It was. Incidentally, the basis weight of the resulting surface sheet was 25 g / m ^2.

(Production of second sheet)
A synthetic fiber made of a polyethylene / polyethylene terephthalate composite resin having a fiber diameter of 2.2 dtex is passed through a card machine to form a web. The web is introduced into a hot air spraying apparatus, subjected to hot air treatment by air-through processing, and then roll embossed. A second sheet was obtained. The obtained second sheet had a thickness of 0.3 mm and a basis weight of 25 g / m ² .

[Reference example]
A sanitary napkin was prepared in the same manner as in Example 1 except that triacylglycerol was not applied to the absorber, and this was used as a sample of a reference example.

[Comparative Example 1]
A sanitary napkin was prepared in the same manner as in Example 1 except that the hemagglutinating agent was not applied to the absorber, and this was used as a sample of Comparative Example 1.

[Comparative Example 2]
A sanitary napkin was prepared in the same manner as in Example 1 except that neither hemagglutinating agent nor triacylglycerol was applied to the absorber, and this was used as a sample of Comparative Example 2.

〔Evaluation test〕
About the sanitary napkin of each Example, a comparative example, and a reference example, the static absorption time was evaluated by the following method. The results are shown in Table 2 below.

<Static absorption time>
A sample to be evaluated is spread and placed on a laboratory table, and an acrylic injection plate in which an acrylic injection cylindrical portion having a cylinder height of 50 mm having an injection hole having a diameter of 1 cm is integrally formed on the sample is injected. Place the hole so that the hole is located at the center of the excretory part facing part on the skin facing surface (surface sheet side) of the sample, put an appropriate weight plate (including the injection plate itself), and the load is 0.85 g / It was adjusted cm ² to become so. 3 g of defibrinated horse blood is injected into the cylinder of the injection plate up to 9 g at intervals of 3 minutes. From the moment when the injection is completed up to 9 g, the defibrinated horse blood in the cylinder disappears and the surface sheet of the sample is exposed. The time (seconds) was measured. The defibrinated horse blood used here is the same as the simulated blood. Each sample was measured three times, and the average value was taken as the static absorption time of the sample. The shorter the static absorption time, the better the menstrual blood absorption performance and the higher the rating.

  As shown in Table 2, Example 1 has the shortest static absorption time, that is, Example 1 has the most excellent menstrual blood absorption performance. From the comparison between Example 1 and other examples, it can be seen that it is effective to contain both the hemagglutinating agent and triacylglycerol in the absorbent body in order to improve the menstrual blood absorption performance.

1 Sanitary napkin (absorbent article for sanitary use)
2 Top sheet 20, 20a, 20b Recessed part 21 Convex part 22 Partition area 23 Surface material slit 3 Back sheet 4 Absorber 41 Central absorbent sheet 42 Main body absorbent sheet 43 Absorber slit 5 Second sheet 6 Side sheet 10 Absorbent body 11 Menstrual Blood 12 Liquid Component 13 Non-Liquid Component 14 Superabsorbent Polymer 15 Coating 16 Agglomerate

Claims (7)

An absorbent body having a longitudinal direction corresponding to the front-rear direction of the wearer and a lateral direction perpendicular thereto, and comprising a superabsorbent polymer, and the skin of the wearer when worn on the skin facing surface side of the absorbent body A sanitary absorbent article comprising as a constituent member a surface sheet that can be contacted,
The constituent member of the absorbent article includes a hemagglutinating agent-containing member containing a hemagglutinating agent,
Physiology containing triacylglycerol in the hemagglutinating agent-containing member, or other components that are disposed closer to the wearer's skin than the hemagglutinating agent-containing member when worn and do not contain the hemagglutinating agent Absorbent articles.   The hemagglutinating agent-containing member is the absorber, and an absorber slit in which the hemagglutinating agent is unevenly distributed and extends in the vertical direction is formed in a skin facing surface side surface portion of the absorber. Sanitary absorbent article.   The sanitary absorbent article according to claim 2, wherein the absorbent slit is wider at a portion relatively closer to the wearer's skin than at a portion relatively distant from the wearer's skin. The absorbent body is overlapped with the central absorbent sheet disposed opposite to the excretory part of the wearer when worn, and overlaps the central absorbent sheet, and extends outward from at least a part of the peripheral edge of the central absorbent sheet. A laminated structure comprising a main body absorbent sheet having a portion;
The sanitary absorbent article according to claim 2 or 3, wherein the absorber slit penetrates at least one layer of the laminated structure in the thickness direction.   The triacylglycerol is contained in the absorbent body, and the content of the triacylglycerol per unit area is higher than that of the hemagglutinating agent in the skin facing surface side surface portion of the absorbent body. The sanitary absorbent article according to any one of the above.   The sanitary absorbent article according to any one of claims 1 to 5, wherein a surface material slit is formed in the surface sheet so as to penetrate the surface sheet in the thickness direction and extend in the longitudinal direction.   The liquid permeable second sheet is arranged as the other constituent member between the top sheet and the absorber, and the triacylglycerol is contained in the second sheet. A sanitary absorbent article according to claim 1.